Marwan Sabbagh MD Page 1 3/17/2015

CURRICULUM VITAE

MARWAN NOEL SABBAGH, M.D., FAAN, CCRI

BIRTH DATE: December 18, 1965

OFFICE ADDRESS: Banner-Sun Health Research Institute10515 W. Santa Fe Dr

Sun City, AZ 85351

OFFICE PHONE/FAX: (623) 832--6500/ 832-6504E-MAIL: Marwan.Sabbagh@bannerhealth.com

CURRENT POSITION: Director, The Cleo Roberts Center for Clinical ResearchSenior Scientist, Haldeman Lab for Molecular Diagnostics and TherapeuticsBanner-Sun Health Research InstituteSun City, AZ

Research ProfessorDepartment of NeurologyUniversity of Arizona College of Medicine-PhoenixPhoenix, AZ

Steering Committee MemberAlzheimer Disease Cooperative StudyAlzheimer’s Disease Neuroimaging Initiative

Associate DirectorClinical CoreArizona Alzheimer’s Disease Center

Board of DirectorsUnited Council of Neurological SubspecialtiesMinneapolis, MN

PREVIOUS POSITIONS: Director (2011-2015)Banner-Sun Health Research InstituteSun City, AZ

Adjunct Assistant Clinical Professor (2000-2004)Department of NeurosciencesSchool of MedicineUniversity of California, San DiegoSan Diego, CA

Assistant Professor (1997-2000)Department of Neurosciences and Department of Neurological SurgerySchool of MedicineUniversity of California, San Diego San Diego, CA

Clinical Instructor (1995-1997)Department of NeurosciencesSchool of MedicineUniversity of California, San Diego San Diego, CA

Associate Director (1997-2000)Neuroscience Center at Alvarado Hospital

San Diego, CA

Attending Physician (1995-2000)UCSD Medical CenterSan Diego, CA

Staff Physician (1995-2000)Alzheimer's Disease Research Center (ADRC)University of California, San DiegoSan Diego, CA

Assistant Clinical Professor of Pharmacy Practice (1998-2000)Western College of PharmacyPomona, CA

Volunteer Physician (1995-2000)St Vincent De Paul Medical ClinicSan Diego, CA

Volunteer Physician (2000-2005)St. Vincent De Paul ClinicPhoenix, AZ

Staff Neurologist (2003-2007)Phoenix Indian Medical CenterPhoenix, AZ

Visiting Scientist (2000-2006)Department of NeurologyMayo Clinic ScottsdaleScottsdale, AZ

Adjunct Professor (2004-2009)College of NursingArizona State UniversityTempe, AZ

Adjunct Professor (2003-2008)Physician Assistant, Osteopathic and Podiatry ProgramsMidwestern UniversityGlendale, AZ

Chief Medical-Scientific Officer and Research Medical Director (2008-2011)Banner-Sun Health Research InstituteSun City, AZ

Clinical Instructor (2000-2008)Geriatric Fellowship Program.Sun Health/ St Joseph’s HospitalsPhoenix, AZ

Board of Directors (2005-2011)Chairman of Medical-Scientific Advisory Committee Desert Southwest ChapterAlzheimer’s AssociationPhoenix, AZ

Co-Director (2007-2010)Clinical Therapeutics CoreArizona Alzheimer’s RegistryArizona Alzheimer’s Consortium

2

Chairman-Scientific Advisory Board (2008-2012)Amerisciences IncorporatedHouston, TX

TRAINING: Fellowship (Geriatric Neurology & Dementia) 1995-1997 under the mentorship of Drs Leon Thal and Robert Katzman

Department of NeurosciencesUniversity of California, San Diego, School of MedicineSan Diego, California

Residency (Neurology) 1992-1995Baylor College of MedicineHouston, Texas

Internship (Internal Medicine) 1991-1992Good Samaritan Regional Medical CenterPhoenix, Arizona

EDUCATION: M.D. - University of Arizona College of Medicine, 1991B.A. - University of California - Berkeley, 1987

HONORS/AWARDS: Student Summer Fellow, Arizona Cancer Society, 1988Student Representative to the Western Federation of Clinical Research, University of Arizona, 1990Allistair Karmody Award Finalist, 1991Travel Fellowship Award Recipient, American Neurological Association,

1996Peter F Drucker Award Co-recipient, 1998 Dystonia Doctor of Excellence, San Diego County, 2000Life Member of the National Registry of Who’s Who #172142, 2001Arizona Business Journal, Healthcare Hero Finalist 2004Fellow of the American Academy of Neurology 2004

BOARDS: Diplomate of the National Board of Medical Examiners, 1992, Certificate #407526Diplomate of the American Board of Psychiatry and Neurology, 1996, Certificate # 43257, Recertified in 2007Certified Clinical Research Investigator #03-F052Diplomate of the UCNS Board of Geriatric Neurology

LICENSES: Arizona Medical License, 1994 (AZ#22378)California Medical License, 1995 (CA#G08170)Medicare UPIN#G13648AHCCCS#540113

HOSPITAL AFFILIATIONS: Banner Boswell Medical Center, Sun City, AZ

MEMBERSHIPS: American Medical Association, 1988-1993American Federation of Clinical Research, 1988-1991American College of Physicians, 1991-1997American Academy of Neurology, 1992-PresentSan Diego Neurological Society, 1995-2000Society for Neuroscience, 1997- 2005Arizona Geriatric Society 2001-PresentSociety for Behavioral and Cognitive Neurology, 2001-2008

EDITOR FOR: Journal of Alzheimer’s Disease (associate editor) Alzheimer’s Disease and Associated Disorders (editorial board)BMC Neurology (section editor-dementia)American Journal of Alzheimer’s Disease (editorial board)

3

Expert Opinion on Investigational Drugs (editorial board)

AD HOC REVIEWER FOR: The Journal of Neuropsychiatry and Clinical NeurosciencePhysiology and BehaviorGrants Committee - Alzheimer’s AssociationBrain ResearchNeurobiology of AgingNeurologyArchives of NeurologyClinical Neurosciences and Disease Study Section CND-1, NIHNeuropharmacology Small Business, ZRG1 BDCN-A (11) B, CSR, NIHEmerging Technology and Training in Neuroscience, ETTN, CSR, NIHAging Program Project Review ZRG1 BDCN-L 42PAlzheimer's Disease Pilot Clinical Trials ZRG1 BBBP-V (55) REuropean Archives of Psychiatry and Clinical NeurosciencesJournal of Clinical PsychiatryNeuroscience LettersNeuroepidemiologyBiological PsychiatryInternational Journal of Geriatric Psychiatry

PUBLICATIONS:Books1. Sabbagh MN, The Alzheimer’s Answer: Reduce Your Risk and Keep Your Brain Healthy, 2008, 2010

(paperback) John Wiley and Sons, Hoboken, New Jersey

2. Sabbagh MN, Alzheimer: Guia practica: Respuestas a las cuestiones fundamentales, desde su diagnostico hsta como se aplica el tratamiento (Spanish Edition), 2010, RobinBooks, Barcelona, Spain

3. Martin G, Sabbagh MN (eds) Palliative Care For Advanced Alzheimer’s and Dementia: Guidelines and Standards for Evidence Based Care, 2010, Springer Publishing Company, New York, NY.

4. Sabbagh M, MacMillan B. The Alzheimer’s Prevention Cookbook: Recipes to Boost Brain Health. 2012, TenSpeed Press, Emeryville, California

5. Nair A, Sabbagh MN (eds) Geriatric Neurology 2014, Wiley Oxford, United Kingdom

Invited Chapters1. Smith RG, Sabbagh M, White P, Brod S: Oral tolerance therapy of autoimmune disease. In Appel SH

(ed) Current Neurology 1996, Mosby, New York, 16:165-189.

2. Shaibani AT, Sabbagh MN, Khan B. Pathological Human Crying. In Ad J.J.M Vingerhoets, Randolph R. Cornelius (eds) Adult Crying :A Biopsychosocial Approach, 2002, Brunner-Routledge, East Sussex, UK

3. Sparks DL, Connor DJ, Browne PJ, Wasser DR, Lopez JE, Sabbagh MN The Alzheimer’s disease atorvastatin treatment trial: scientific basis and position on the use of the HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier. In Fillit H., O’Connell AW. Drug Discovery and Drug Development for Alzheimer’s Disease 2002, Springer Publishing Company, New York, 244-252.

4. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolowski C, Lochhead J, Browne P. Cholesterol, copper, and statin therapy in AD. In Gauthier S, Schelten P, Cummings J, Alzheimer’s Disease and Related Disorders Annual 5, 2005, Taylor and Francis, London, 89-110.

5. Reisberg B, Weigel J, Franssen E, Kadiyala S, Auer S, Souren L, Sabbagh M, Golomb J. Clinical features of severe dementia-staging. In Burns A, Winblad B (eds) Severe Dementia 2006, John Wiley and Sons, Hoboken, New Jersey, 95-127.

6. McCarthy M, Gallagher M, Sabbagh M. Appropriate use of medications in advanced dementia. In Long C (ed) Palliative Care for Advanced Dementia: Guidelines and Standards 2006, Alzheimer’s Association Desert Southwest Chapter, Phoenix AZ, 40-51.

4

7. Rogers J; Beach T; Li R; Liang Z; Lue, L.-F; Roher A; Sabbagh M; Shen Y; Strohmeyer R; Walker D. Inflammatory mechanisms in Alzheimer's disease and other neurodegenerative disorders. In: Chemistry and Molecular Aspects of Drug Design and Action (Kourounakis and Rekka, eds.). CRC Press (Boca Raton, FL), pp. 3-12, 2007.

8. Barry Reisberg, Jerzy Wegiel, Emile Franssen, Sridhar Kadiyala, Stefanie Auer, Liduïn Souren, Marwan Sabbagh and James Golomb Clinical Features of Severe Dementia: Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons, Hoboken NJ. Chapter 8

9. Reisberg, B., Jamil, I.A., Khan, S., Monteiro, I., Torossian, C., Ferris, S., Sabbagh, M., Gauthier, S., Auer, S., Shulman, M.B., Kluger, A., Franssen, E., and Wegiel, J., Staging dementia. In: Principles and Practice of Geriatric Psychiatry, 3rd. edition, M. T. Abou-Saleh, C. Katona, and A. Kumar (Eds.), Chichester, England, Wiley-Blackwell, 2010, p. 162-169.

10. Belden CM, Burciu C, Sabbagh M (2014). Global Deterioration Scale (Individuals). In: Michalos AC (Ed.). Encyclopedia of Quality of Life and Well-Being Research. Springer, Dordrecht, Netherlands: Springer, pp 2562-2564

11. Sabbagh MN, Nair AK, Approach to the Geriatric Neurology Patient: The Neurologic Examination. In Nair A, Sabbagh MN (eds) Geriatric Neurology 2014, Wiley Oxford p71-84

12. Nair AK, Sabbagh MN. Amyloid imaging. In Nair A, Sabbagh MN (eds) Geriatric Neurology 2014, Wiley Oxford p. 162-169

13. Singh J, Sabbagh MN, Nair AK. Evidence based pharmacological treatment of dementia. In Nair A, Sabbagh MN (eds) Geriatric Neurology 2014, Wiley Oxford, p 557-573.

14. Decourt B1*, Macias M1, Berk C1, Sabbagh M1, Adem A2. BACE1 inhibitors: attractive therapeutics for Alzheimer’s disease. In Ur-Rahman A, Choudhary MI, Frontiers in Drug Design and Discovery 2014 Bentham Science, p518-546.

Invited Reviews and Editorials1. Taher A, Sabbagh M, Doody R; Laughter and crying in neurologic disorders. Neuropsychiatry

Neuropsychology & Behavioral Neurology 7(4): 243-250, 1994.

2. Sabbagh MN, Galasko D, Thal LJ. Beta amyloid and treatment opportunities for Alzheimer's disease. Alzheimer's Disease Reviews 1998; 3:1-19.

3. Shaibani AT, Sabbagh MN. Pseudo-Neurologic Syndromes: Recognition and Diagnosis. American Family Physician 1998; 57(10): 2485-2494.

4. Sabbagh, MN. Application of the Changing Therapies for Alzheimer’s Disease in Clinical Practice, American Speech and Language Association 1998; 3(1): 7-12.

5. Sabbagh MN, Galasko D, Koo, E., Thal LJ. β-amyloid and treatment opportunities for Alzheimer's disease. Journal of Alzheimer's Disease 2000; 2(3-4): 231-259.

6. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer’s disease and why it would be ill-advised to use one that crosses the blood-brain barrier. Journal of Nutrition, Health, and Aging, 2002 6(5): 324-330.

7. Sparks DL, Connor DJ, Browne P, and Sabbagh MN. Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated. Journal of Molecular Neuroscience 2002; 19: 209-212.

8. Sabbagh MN, Lukas RJ, Sparks DL, Reid RT. The nicotinic acetylcholine receptor, smoking, and Alzheimer’s disease. Journal of Alzheimer’s Disease, 2002; 4 (4): 317-325.

9. Sparks DL, Sabbagh MN, Breitner JCS, Hunsaker J. Is cholesterol a culprit in AD. International Psychogeriatrics, 2003; 15 (suppl1): 153-159.

5

10. Sabbagh MN, Farlow MR, Relkin NR, Beach TG. Do cholinergic therapies have disease modifying effects in Alzheimer’s disease? Alzheimer’s and Dementia 2006;2(2): 118-125.

11. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P. Statin therapy in AD. Acta Neurologica Scandinavica 2006; 185:S78-86

12. Thind K, Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimer’s Disease, PanMinerva Medica 2007; 49(4):191-195.

13. Beach TG, Sue LI, Walker DG, Roher AE, Lue, LF, Vedders L, Connor DJ, Sabbagh M, Rogers J. The Sun Health Research Institute Brain Donation Program: Description and Experience 1987-2007 Cell Tissue Bank. 2008 Mar 18; [Epub ahead of print]

14. Sabbagh MN, Richardson S, Relkin N. Disease modifying approaches to Alzheimer's disease: Challenges and opportunities. Lessons from donepezil therapy” Alzheimer’s and Dementia 2008 4(1): S109-S118.

15. Sabbagh MN. Commentary on the baseline data of the atorvastatin/donepezil study for Alzheimer’s disease. Alzheimer’s and Dementia 2008; 4 (3):174-175.

16. Khatchaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom J, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszinski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JCS, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khatchaturian AS, Bain L. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer’s and Dementia 2008; 4 (3):156-163.

17. Rogers J, Sabbagh MN. Relationships of strokes and non-steroidal anti-inflammatory drug use to apolipoprotein E4-conferred of Alzheimer’s disease and dementia. Neurology 2008; 70:2-4.

18. Quinn J, Sabbagh MN. Editorial: Biochemical Markers in Persons with Pre-Clinical Familial Alzheimer's Disease. Neurology 2008; 71:78-79.

19. Jacobson S, Sabbagh MN. Donepezil: potential neuroprotective and disease modifying effects. Expert Opinion on Drug Metabolism and Toxicology 2008; 4(10):1363-1369.

20. Beach TG, White CL, Sabbagh MN, Shill HA, Adler CH. Response to Parkinnen et al and Jellinger, Acta Neuropathologica 2008; Nov 4 [epub ahead of print]

21. Lue LF, Jacobson S, Walker D, Sabbagh MN. The receptor for advanced glycation end-products: its role in Alzheimer’s and other diseases. Future Neurology 2009; 4(2): 167-177.

22. Sabbagh MN, Tariot PN. Commentary on A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. A national registry to identify a cohort for Alzheimer’s disease prevention studies. Alzheimer’s and Dementia 2009;5: 128-129.

23. Khachaturian ZS,*; Snyder PJ, Doody RS, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Phelps C, Roses A, Simpkins JW; Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W; Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O; Petersen RC, Mohs RC, Buckholtz N, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N; Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimer’s and Dementia 2009; 5:85-92.

24. Sabbagh MN. Drug Development for Alzheimer’s Disease: Where Are We Now and Where Are We Headed. American Journal of Geriatric Pharmacotherapy 2009; 7(3): 167-185.

25. Sabbagh MN, Thind K, Sparks DL. On cholesterol levels, and statins in Alzheimer’s disease and cognitive decline: progress and setbacks. Alzheimer’s Disease and Associated Disorders 2009 (Oct-Dec); 23(4):303-305.

6

26. Beach TG, White CL, Sabbagh MN, Shill HA, Adler CH. Response to Parkinnen et al. and Jellinger. Acta Neuropathol. 2009 Feb;117(2):217-218.

27. Sabbagh MN, Shill HA, Dimebon (latrepirdine), a potential treatment with a novel mechanism of action for the treatment of Alzheimer's disease and Huntington disease, Current Opinion in Investigational Drugs 2010; Curr Opin Investig Drugs. 2010 Jan;11(1):80-91.

28. Arab L, Sabbagh MN. Lifestyle changes, do they lower Alzheimer’s risk? Journal of Alzheimer’s Disease 2010;20(3):785-94. Review. PubMedPMID: 20182018

29. Sabbagh MN. Commentary On The Perspective: Design Of Comprehensive Alzheimer's Disease Centers To Address Unmet National Needs by JQ Trojanowski et al. Alzheimer’s and Dementia 2010 Mar;6(2):156-7. No abstract available.

30. Khachaturian AS, Sabbagh M. Commentary on "Developing a national strategy to prevent dementia: Leon Thal Symposium 2009." Creating a national database for successful aging. Alzheimers Dement . 2010 Mar;6(2):132-4. No abstract available

31. Zaven Khachaturian [Convener – Facilitator] - Presenters: Deborah Barnes, Richard Einstein, Sterling Johnson, Virginia Lee, Allen Roses, Mark A. Sager, William R. Shankle, Peter J. Snyder, Ronald C. Petersen, Gerard Schellenberg and John Trojanowski - Discussants: Paul Aisen, Marilyn S. Albert, Charles Bernick, John C. S. Breitner, Neil Buckholtz, Maria Carrillo, Steven Ferris, Barry D. Greenberg, Michael Grundman Ara S. Khachaturian, Lewis H. Kuller, Oscar L. Lopez, Paul Maruff, Richard C. Mohs, Marcelle Morrison-Bogorad, Creighton Phelps, Michael Phillips, Stephen Rao, Eric Reiman, Marwan Sabbagh, Mary Sano, , Randy Schiffer, Lon S. Schneider, Eric Siemers, Pierre Tariot, Jacques Touchon, Bruno Vellas, Reporter: Lisa J. Bain. Developing a National Strategy to Prevent Dementia. Alzheimer’s and Dementia 2010 Mar;6(2):89-97.

32. Sabbagh MN, Berk C. Latrepirdine for Alzheimer’s disease: trials and tribulations. Future Neurology 2010 September 2010, Vol. 5, No. 5, Pages 645-651.

33. Sabbagh MN, Cummings J Progressive Cholinergic Decline in Alzheimer’s Disease: Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011; 11:21

34.DeCourt B, Sabbagh MN. BACE1 as a potential biomarker for Alzheimer’s disease. Journal of Alzheimer’s Disease. 2011;24 Suppl 2:53-9]

35.Jacobson SA, Sabbagh MN. Investigational drugs for the treatment of Alzheimer’s disease: failed trials. Alzheimer’s Research and Therapy 2011 Apr 15;3(2):14. [Epub ahead of print]

36. Patel S, Shah R, Coleman P, Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of Alzheimer’s Disease International Journal of Alzheimer’s Disease ;2011:572495. Epub 2011 Oct 23.

37. Mehta M, Adem A, Sabbagh MN. The nicotinic receptor, smoking and Alzheimer’s revisited, Frontiers in Bioscience E4, 169-180, January 1, 2012.

38. Sabbagh MN ,Berk C, Appraisal of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease, International Journal of Alzheimer’s Disease 2012;2012:707468. Epub 2011 Dec 1.

39. Arab L, Sadeghi R, Walker DG, Lue LF, Sabbagh MN, Consequences of aberrant insulin regulation in the brain: Can treating diabetes be effective for Alzheimer’s Disease. Current Neuropharmacology 2011; 9(4): 693-705.

40. Mehta M, Adem A, Sabbagh MN. New acetylcholinesterase inhibitors for Alzheimer's Disease. International Journal on Alzheimer’s Disease Volume 2012 (2012), Article ID 728983, 8 pagesdoi:10.1155/2012/728983

7

41. Sabbagh MN, Sparks DL. Statins to treat Alzheimer’s: an incomplete story. Expert Review in Neurotherapeutics January 2012, Vol. 12, No. 1, Pages 27-30.

42. Sabbagh MN, Porsteinsson AP, Nair A, Adem A., Novel Therapeutics in Alzheimer's Disease International Journal on Alzheimer’s Disease Volume 2012 (2012), Article ID 207969, 2 pages

43. Sabbagh MN, Geula C, Messis C, Friedland R. Conference Report on the 5 th International Conference on Alzheimer’s Disease in the Middle East, May 7-9, 2009, Limmassol Cyprus. Journal of Alzheimer’s Disease.. 2012 May 21Epub ahead of print] No abstract available. PMID:22614876

44. Lue LF, Andrade C, Sabbagh MN, Walker DG. Is there inflammatory synergy in type II diabetes mellitus and Alzheimer’s disease International Journal of Alzheimer’s Disease 2012:918680. Epub 2012 Jun 21.

45. Sabbagh MN, Ahmadi MM, Belden C. The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging, Expert Review of Neurotherapeutics 2012 Jun;12(6):637-9

46. Jeffrey L. Cummings,1 David Geldmacher,2 Martin Farlow,3 Marwan Sabbagh,4 Daniel Christensen5 & Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer’s Disease: Drug Profile and Clinical Guidelines. CNS Neurosci Ther . 2013 Mar 6. doi: 10.1111/cns.12076. [Epub ahead of print]

47. DeCourt B, Mobley W, Reiman E, Shah RJ, Sabbagh MN. Recent perspectives on Alzheimer’s disease pathological changes in Down syndrome” J Alzheimers Dis Parkinsonism 2013, S7 http://dx.doi.org /10.4172/2161-0460.S7-002

48. Adem A, El-Agnaf O, Sabbagh MN. Neurodegeneration: The first IBRO-Middle East Neuroscience Conference. Current Alzheimer’s Research 2013; 10 (6):557-8.

49. Berk C, Sabbagh MN. Drugs in Late Stage Development for Alzheimer’s Disease. Drugs Aging. 2013 Aug 14. [Epub ahead of print]

50. Berk C, Paul G, Sabbagh MN. Investigational Drugs in Alzheimer’s Disease: Current Progress. Expert Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs. 2014 Jun;23(6):837-46. doi: 10.1517/13543784.2014.905542. Epub 2014 Apr 5.

51. Richards D, Sabbagh MN. Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain. Neurology and Therapy. 2014 DOI 10.1007/s40120-014-0022-9

52. Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement . 2014 Dec 12. pii: S1552-5260(14)02860-X. doi: 10.1016/j.jalz.2014.10.007.

53. Walker DG, Lue LF, Paul G, Patel A, Sabbagh MN. Advanced Glycation Endproduct Modulators: A New Therapeutic Target in Alzheimer’s Disease. Expert Opinion in Investigational Drugs. Posted online on January 14, 2015. (doi:10.1517/13543784.2015.1001490)

Peer-Reviewed Manuscripts

1. Adem A, Sabbagh M, Nordberg A: Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex. Journal of Neural Transmission 1988; 72:11-18.

2. Sabbagh M, Garza J, Patten B: Thoracoscopic thymectomy in myasthenia gravis. Muscle & Nerve 1995; 18:1475-1477.

3. Sabbagh M, Lynn P, Jhingran S et al: Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences 1997; 9: 68-74.

8

4. Corey-Bloom J, Sabbagh MN, Bondi MW, Hansen L, Alford MF, Thal LJ: Hippocampal sclerosis contributes to dementia in the elderly. Neurology 1997; 48(1): 154-160.

5. Olichney J, Sabbagh M, Hofstetter RC, Galasko D, Grundman M, Katzman R, Thal L: The impact of apolipoprotein ε4 on the cause of death in Alzheimer’s disease. Neurology, 1997; 49(1): 76-81.

6. Olichney J, Ellis R, Katzman R, Sabbagh M, Hansen L. Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer's disease. Annals of the New York Academy of Sciences 1997; 826: 493-497.

7. Sabbagh MN, Reid R, Corey-Bloom J, Rao T, Lloyd K, Hansen L, Alford M, Masliah, E, Adem A, Thal LJ, Correlation of nicotinic binding to neurochemical markers in Alzheimer’s disease. Journal of Neural Transmission 1998;105(7): 709-717

8. Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thomas R, Masliah E, Thal LJ. Neurochemical markers do not correlate with cognitive decline in the Lewy Body Variant of Alzheimer’s disease, Archives of Neurology 1999; 56(12): 1568-1572.

9. Tiraboschi P, Hansen LA, Sabbagh MN, Schoos B, Alford M, Masliah E, Thal LJ. Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54:407-411.

10. Corey-Bloom J, Tiraboschi P, Hansen LA, Schoos B, Alford M, Sabbagh MN, Masliah E, Thal LJ. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer’s disease. Neurology 2000; 54:403-406.

11. Reid RT, Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thal LJ. Nicotinic receptor in dementia with Lewy Bodies: comparisons with Alzheimer’s disease. Neurobiology of Aging, 2000; 21 (5): 741-746.

12. Reid,RT, Sabbagh MN, Thal LJ. Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimer's disease? J Neural Transmission, 2001; 108(8-9): 1043-1050.

13. Sabbagh MN, Reid RT, Hansen LA, Alford M, Thal LJ. Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer’s disease and dementia with Lewy bodies. J Neural Transmission, 2001; 108 (10): 1149-1157

14. Caselli R, Beach T, Sue L, Connor DJ, Sabbagh MN. Progressive Aphasia with Lewy Bodies, Dementia and Geriatric Cognitive Disorders, 2002; 14 (2): 55-58.

15. Sabbagh M, Silverberg N, Majeed B, Samant S, Sparks DL, Seward J, Connor DJ. Length of stay in skilled nursing facilities is longer for patients with dementia. J Alz Dis 2003; 5(1): 57-63.

16. Smith RG, Roher A, Appel SH, Doody RS, Killian DM, Corey-Bloom J, Sabbagh MN. Autonomic sudomotor dysfunction discriminates Alzheimer’s disease and non-demented control individuals. Current Medicinal Chemistry: Immunology, Endocrine and Metabolic Agents 2003; 3:233-243.

17. Reid RT, Sabbagh MN. Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor Levels In Vivo and In Vitro. Journal of Alzheimer’s Disease 2003; 5(6): 429-436.

18. Caviness JN, Adler CH, Sabbagh M, Connor DJ, Hernandez JL, Lagerlund T. Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinson’s Disease Movement Disorders 2003; 18 (10): 1157-62.

19. Beach TG, Sue L, Scott S, Layne K, Newell A, Walker D, Baker M, Sahara N, Yen S-H, Hutton M, Caselli R, Adler C, Connor D, Sabbagh M. Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003; 13: 263-278.

20. Sparks DL, Lopez J, Sabbagh M, Connor D, Seward J, Browne P. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial. J Molecular Neuroscience 2003; 20: 407-410.

9

21. Caselli RJ, Beach TG, Sue LI, Connor DJ, Sabbagh MN. Progressive aphasia with Lewy bodies. Dementia Review Series 2003; 4: 10-11.

22. Sabbagh MN, Thompson N, Tweedy D, Stipho-Majeed S, Kawas C, Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimer’s Disease Clinical Trials. Pharmaceutical Regulation and Development 2003; 1(4): 269-276.

23. Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment. Neuropsychologia 2004, 42(7), 980-989.

24. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y. Amyloid {beta} peptide load is correlated with increased {beta}-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2004 Mar 9; 101(10):3632-3637.

25. Tiraboschi P, Sabbagh MN, Hansen LA, Salmon DP, Merdes A, Gamst A, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Alzheimer’s disease without neocortical neurofibrillary tangles: “a second look”. Neurology 2004; 62:1141-1147.

26. Davie JE, Azuma T, Goldinger SD, Connor DJ, Sabbagh MN, Silverberg N. Sensitivity to Expectancy Violations in Healthy Aging and Mild Cognitive Impairment. Neuropsychology 2004; 18(2): 269-275.

27. Sabbagh MN, Silverberg NB, Descheny RL, Baxter LC, Connor DJ, Crocker-Sabbagh IP, Dementia with Lewy bodies in a Native American. Alzheimer’s Disease and Associated Disorders 2004; 18 (4):259-261.

28. Sabbagh MN, Zahiri HR, Ceimo J, Cooper K, Gaul W, Connor DJ, Sparks DL. Is there a characteristic lipid profile in Alzheimer’s disease? Journal of Alzheimer’s Disease 2004; 6 (6): 585-589.

29. Sabbagh MN, Tyas SL, Emery SC, Hansen LA, Alford MF, Reid RT, Tiraboschi P, Thal LJ, Smoking Affects the Phenotype of Alzheimer’s Disease Neurology 2005; Apr 12;64(7):1301-3.

30. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolwolski C. Benefit of Atorvastatin in the treatment of mild to moderate Alzheimer’s disease: results from the Alzheimer’s disease cholesterol lowering treatment (ADCLT) trial. Archives of Neurology 2005; 62:753-757.

31. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Johnson-Traver S, Lochhead J, Ziolwolski C. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD. Current Alzheimer’s Research 2005 Jul;2(3):343-53

32. Sabbagh, MN; Silverberg N; Bircea S; Majeed, B; Samant S; Caviness, JN; Reisberg, B, Adler CH. Is the functional decline in PD similar to the functional decline of AD? Parkinsonism and Related Disorders 2005 11: 311-315.

33. Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in Dementia with Lewy Bodies. Journal of Alzheimer’s Disease 2005; 7(4): 285-289.

34. Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolowski C, Lochhead J, Browne P. Cholesterol, copper, and A in controls, MCI, AD, and the AD Cholesterol Lowering Treatment Trial. Current Alzheimer’s Research 2005; 2:527-539.

35. Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, Cao P, Kolody H, Vedders L, Kolb WP, Sabbagh M. Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes. Neurobiology of Aging 2006; 27:1733-1739.

36. Caviness, JN, Shill HA, Sabbagh, MN, Evidente VGH, Hernandez J Adler CH, Cortico-Muscular coherence is increased in the small postural tremor of Parkinson’s disease. Movement Disorders 2006; 21 (4):492-499.

10

37. Sabbagh MN, Sandhu S, Lahti T, Kolody H, Silverberg NB, Sparks DL. What is the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer’s disease? Current Alzheimer’s Research 2006; 3(2): 157-160.

38. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype, and dementia severity influence the benefit of atorvastatin treatment in AD: Results from the Alzheimer’s disease Cholesterol Lowering Treatment Trial. Acta Neurologica Scandinavica 2006; 185: S3-7.

39. Roher, AE, Garami Z, Alexandrov AV, Kokjohn TA, Esh CL, Kalback WM, Vedders LJ, Wilson JR, Beach TG, Sabbagh MN, Interaction of cardiovascular disease and neurodegeneration: Transcranial Doppler ultrasonography and Alzheimer’s disease. Neurological Research 2006; Sep;28(6):672-8.

40. Baxter LC, Sparks DL, Johnson SC, Lenoski B, Lopez.JE, Connor DJ, Sabbagh MN. MRI Relationship of cognitive measures and gray and white matter in Alzheimer's Disease. Journal of Alzheimer's Disease. 2006 Aug;9(3): 253-260.

41. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Connor DJ, Sabbagh MN, Walker D, Roher A Circle of Willis Atherosclerosis: Association with Alzheimer’s Disease, Neuritic Plaques and Neurofibrillary Tangles. Acta Neuropathologica 2006 Sep 20; epub ahead of print

42. Valla J, Coon K, Caselli R, Sabbagh MN, Ahern G, Baxter L, Alexander G, Walker DG, Reiman EM. Impaired Platelet Mitochondrial Activity in Alzheimer’s disease and Mild Cognitive Impairment. Mitochondrion. 2006 Dec; 6(6): 323-330.

43. Sabbagh MN, Shah F, Reid RT, Sue L, Peterson LK, Beach TG. Pathological and Nicotinic Receptor Binding Differences between Mild Cognitive Impairment, Alzheimer’s disease and Normal Aging, Archives of Neurology 2006 Dec; 63 (12): 1771-76.

44. Baxter LC, Sabbagh MN, Voxel-based morphometry in Alzheimer’s patients. Journal of Alzheimer’s Disease. 2006 Dec; 10 (4):449.

45. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Connor DJ, Sabbagh MN, Walker D, Roher A Circle of Willis Atherosclerosis: Association with Alzheimer’s Disease, Neuritic Plaques and Neurofibrillary Tangles. Acta Neuropathologica 2007; 113(1):13-21.

46. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Noble B, Evidente VGH, Shill HS, Adler CH, Defining mild cognitive impairment in Parkinson’s disease (PD-MCI), Movement Disorders 2007 Apr 5;22(9):1272-1277

47. Caviness, JN, Hentz, J, Evidente VGH, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Electroencephalography as a biomarker for cognitive state in Parkinson’s disease. Parkinsonism and Related Disorders 2007 Mar 7; [Epub ahead of print]

48. Lyketsos CG, Breitner JCS, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M for the ADAPT Research Group, No immediate reduction in AD incidence with naproxen and celecoxib: results from a randomized prevention trial. Neurology 2007; May 68: 1800-1809.

49. Beach TG, Sue LI, Walker DG, Lue LF, Caviness J, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathologica 2007; 114:419-424.

50. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Mahant P, Samanta J, Burns RS, Evidente VGH, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH, Functional decline correlates with cognitive impairment in Parkinson’s disease and Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2007:24:327-334.

51. Ray S*, Britschgi M*, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DF, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA,

11

Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins. Nature Medicine 2007 Oct 14; [Epub ahead of print]

52. Beach TG, Adler CH, Sue LI, Peirce JB, BachalakuriJ, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease, Acta Neuropathol. 2007 Nov 6; [Epub ahead of print]

53. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathological findings in prospectively ascertained essential tremor subjects. Neurology 2008 Apr 15;70(16 Pt 2):1452-5.

54. Sparks DL, Lemieux SK, Haut MW, Baxter LC, Johnson SC, Sparks LM, Sampath H, Lopez JE, Sabbagh MN, Connor DJ. Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial. Cleve Clin J Med. 2008 Mar;75 Suppl 2:S87-93.

55. Griffin-Pierce T, Silverberg N, Jim M, Connor D, Peters J, Kaszniak A, Sabbagh M, Challenges to developing neuropsychological instruments for assessing Alzheimer’s disease in American Indians and Alaska natives. Alzheimer’s and Dementia 2008; 4: 291-299.

56. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach T, Adler C, Dunckley T, Neuronal gene expression correlates of Parkinson’s disease with dementia. Movement Disorders 2008; Jul 22 [epub ahead of print].

57. Sparks DL, Kryscio R, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with selective statin use in a clinical trial cohort. Current Alzheimer’s Research 2008; 5(4): 416-421.

58. Sparks DL, Ziolkowski C, Connor D, Beach T, Adler C, Sabbagh M. et al. Copper and cognition in Alzheimer’s and Parkinson’s disease. Cell Biol Toxicol 2008 24: 423-470.

59. Reid RT, Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. Journal of Neural Transmission 2008 Aug 26 [epub ahead of print].

60. Sabbagh MN, Lue LF, Reid RT, Walker DG. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw,Ind) Neuroscience Letters 2008; 448: 217-220

61. Connor DJ, Sabbagh MN. Administration and scoring variance on the ADAS-cog. Journal of Alzheimer’s Disease 2008; 15 (3): 461-464.

62. Connor DJ, Sabbagh MN, Cummings JL. Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials. Alzheimer’s and Dementia 2008; 4(6):390-394.

63. Beach TG, White CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue L, Sasse J, Bachalakuri J, Henry-Watson, Akiyama JH, Adler CH, Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders, Acta Neuropathologica 2009 Feb;117(2):169-74.

64. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH; Seward JD; Beach TG, Sabbagh MN. Aβ peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimer’s and Dementia 2009; 5(1): 18-29.

65. Ignatov I, Belden C, Jacobson S, Connor DJ, Sabbagh MN. Alzheimer’s disease in an Apolipoprotein E2 homozygote. Journal of Alzheimer’s Disease 2009 Jan 16(1):35-38.

66. Beach TG, Adler CH, Lue LF, Sue LI, Sasse J; Bachalakuri J, Henry-Watson J, Boyer S; Shirohi S,Brooks R, Eschbacher J, White CL, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG, Unified Staging System for Lewy Body Disorders: Correlation with Nigrostriatal Degeneration, Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun;117(6):613-34

12

67. Caselli RJ, Hentz JG, Osborne D, Sabbagh MN, Connor DJ, Ahern G, Baxter L, Rapcsak S, Hutton MF, Reiman EM, Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect. New England Journal of Medicine 2009;255-263.

68. Driver-Dunckley E, Connor DJ, Hentz J, Sabbagh MN, Silverberg N, Hernandez JE, Vedders L, Evidente V, Shill H, Caviness J, Adler CH. No evidence of cognitive dysfunction or depression in patients with mild RLS. Movement Disorders 2009; Jul 16 [epub ahead of print]

69. Sabbagh MN, Sandhu SS, Farlow MR, Beach TG, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH. Correlation of Clinical Features to Argyrophilic Grains at Autopsy. Alzheimer’s Disease and Associated Disorders 2009; 23(3): 229-233.

70. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Reid RT, Walker DG, Beach TG. Parkinson’s disease with dementia: comparing patients with and without Alzheimer pathology Alzheimer’s disease and Associated Disorders 2009; 23(3): 295-297.

71. Sabbagh MN, Cooper K, Fleming SR, Thind K, Stoehr JD, Lahti T, Reisberg B, Sue L, Vedders L, Beach TG, Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimer’s Pathology in MCI and AD. Current Alzheimer’s Research 2009; Dec 1 [epub ahead of print]

72. Goldknopf IL, Bryson JK, Strelets I, Quintero S, Sheta EA, Mosqueda M, Park HR, Appel SH, Shill H, Sabbagh M, Chase B, Kalidjian E, Markopoulou K. Abnormal Serum concentrations of proteins in Parkinson’s disease. Biomedical Biophysical Research Communications 2009; Aug 31 [epub ahead of print]

73. Driver-Dunckley E, Connor DJ, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente V, Shill HA, Caviness JN, Adler CH, No evidence of cognitive dysfunction or depression in mild restless legs syndrome. Movement Disorders 2009; 1840-1842.

74. Baholavek M, Jiamsripong P, Calleja A, McMahon E, Marouf C, Kokjohn T, Chaffin TL, Vedder LJ, Garami Z, Beach TG, Sabbagh MN, Roher AE. Alzheimer’s disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time. Journal of Ultrasound in Medicine. 2009 Nov;28(11):1493-1500.

75. Soares HD, Chen Y, Sabbagh M, Roher A, Schrivjers E, Breteler M. Identifying early markers of Alzheimer’s disease using quantitative multiplex proteomic immunoassay panels. Annals of the NY Academy of Sciences 2009; 1180: 56-67.

76. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, Van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M for the Bapineuzumab 201 Clinical Trial Investigators. Neurology 2009; epub ahead of print November 18

77. Choi SA; Evidente VGH; Caviness JN; Shill HA; Sabbagh MN; Connor DJ; Hentz JG; Adler CH; Beach TG. Are there differences in cerebral white matter lesion burdens between Parkinson’s disease patients with or without dementia? Acta Neuropathologica 2009; epub ahead of print December 7

78. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM; the Alzheimer's Disease Neuroimaging Initiative, Weiner M, Thal L, Petersen R, Jack CR Jr, Jagust W, Trojanowki J, Toga AW, Beckett L, Green RC, Gamst A, Potter WZ, Montine T, Anders D, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Harvey D, Kornak J, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Vorobik R, Quinn J, Schneider L, Pawluczyk S, Spann B, Fleisher AS, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Mintun MA, Schneider S, Marson D, Griffith R, Badger B, Grossman H, Tang C, Stern J, Detoledo-Morrell L, Shah RC, Bach J, Duara R, Isaacson R, Strauman S, Albert MS, Pedroso J, Toroney J, Rusinek H, de Leon MJ, De Santi SM, Doraiswamy PM, Petrella JR, Aiello M, Clark CM, Pham C, Nunez J, Smith CD, Given CA 2nd, Hardy P, Dekosky ST, Oakley M, Simpson DM, Ismail MS, Porsteinsson A, McCallum C, Cramer SC, Mulnard RA,

13

McAdams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, Devous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Laubinger MM, Bartzokis G, Silverman DH, Lu PH, Fletcher R, Parfitt F, Johnson H, Farlow M, Herring S, Hake AM, van Dyck CH, Macavoy MG, Bifano LA, Chertkow H, Bergman H, Hosein C, Black S, Graham S, Caldwell C, Feldman H, Assaly M, Hsiung GY, Kertesz A, Rogers J, Trost D, Bernick C, Gitelman D, Johnson N, Mesulam M, Sadowsky C, Villena T, Mesner S, Aisen PS, Johnson KB, Behan KE, Sperling RA, Rentz DM, Johnson KA, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Obradov S, Killiany R, Norbash A, Obisesan TO, Jayam-Trouth A, Wang P, Auchus AP, Huang J, Friedland RP, Decarli C, Fletcher E, Carmichael O, Kittur S, Mirje S, Johnson SC, Borrie M, Lee TY, Asthana S, Carlsson CM, Potkin SG, Highum D, Preda A, Nguyen D, Tariot PN, Hendin BA, Scharre DW, Kataki M, Beversdorf DQ, Zimmerman EA, Celmins D, Brown AD, Gandy S, Marenberg ME, Rovner BW, Pearlson G, Blank K, Anderson K, Saykin AJ, Santulli RB, Pare N, Williamson JD, Sink KM, Potter H, Ashok Raj B, Giordano A, Ott BR, Wu CK, Cohen R, Wilks KL, Safirstein BE. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20954-20959.

79. McKinnon J, Evidente V, Driver-Dunckley E, Premkumar A, Hentz J, Shill HA, Sabbagh MN, Caviness J, Connor DJ, Adler CH, Olfaction in the elderly: a cross-sectional analysis comparing with controls and other disorders. Int J Neurosci. 2010 Jan;120(1):36-9.

80. Caselli RJ, Beach T, Sue L, Sabbagh M, Connor D, Walker D, Amyloid load in nondemented autopsied brains correlates with APOEe4, Neuroscience Letters 2010; Feb 11 [epub ahead of print]

81. Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG. Is incidental Lewy Body Disease really incidental? Movement Disorders 2010 Feb 19. [Epub ahead of print]

82. Stieler J, Grimes R, Weber D, Hardy C, Gartner W, Sabbagh MN, Arendt T Multivariate Analysis of Differential Lymphocyte Cell Cycle Activity in Alzheimer's Disease. Neurobiology of Aging 2010 Apr 13. [Epub ahead of print]

83. Beach TG, Adler CH, Sue LI, Vedders L, Lue LF, White CL, Akiyama H, Caviness J, Shill HA, Sabbagh MN, Walker DG. Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders. Acta Neuropathologica 2010 Jun;119(6):689-702. Epub 2010 Mar 21.

84. Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, Liebsack C, Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to MC: results in a clinical trial cohort. Neurodegenerative Diseases 2010;7(1-3):183-6. Epub 2010 Mar 12.

85. Wolk DA, Dickerson BC; the Alzheimer's Disease Neuroimaging Initiative, Weiner M, Aiello M, Aisen P, Albert MS, Alexander G, Anderson HS, Anderson K, Apostolova L, Arnold S, Ashford W, Assaly M, Asthana S, Bandy D, Bartha R, Bates V, Beckett L, Bell KL, Benincasa AL, Bergman H, Bernick C, Bernstein M, Black S, Blank K, Borrie M, Brand C, Brewer J, Brown AD, Burns JM, Cairns NJ, Caldwell C, Capote H, Carlsson CM, Carmichael O, Cellar JS, Celmins D, Chen K, Chertkow H, Chowdhury M, Clark D, Connor D, Correia S, Crawford K, Dale A, de Leon MJ, De Santi SM, Decarli C, Detoledo-Morrell L, Devous M, Diaz-Arrastia R, Dolen S, Donohue M, Doody RS, Doraiswamy PM, Duara R, Englert J, Farlow M, Feldman H, Felmlee J, Fleisher A, Fletcher E, Foroud TM, Foster N, Fox N, Frank R, Gamst A, Given CA 2nd, Graff-Radford NR, Green RC, Griffith R, Grossman H, Hake AM, Hardy P, Harvey D, Heidebrink JL, Hendin BA, Herring S, Honig LS, Hosein C, Robin Hsiung GY, Hudson L, Ismail MS, Jack CR Jr, Jacobson S, Jagust W, Jayam-Trouth A, Johnson K, Johnson H, Johnson N, Johnson K, Johnson KA, Johnson S, Kachaturian Z, Karlawish JH, Kataki M, Kaye J, Kertesz A, Killiany R, Kittur S, Koeppe RA, Korecka M, Kornak J, Kozauer N, Lah JJ, Laubinger MM, Lee VM, Lee TY, Lerner A, Levey AI, Longmire CF, Lopez OL, Lord JL, Lu PH, Macavoy MG, Malloy P, Marson D, Martin-Cook K, Martinez W, Marzloff G, Mathis C, Mc-Adams-Ortiz C, Mesulam M, Miller BL, Mintun MA, Mintzer J, Molchan S, Montine T, Morris J, Mulnard RA, Munic D, Nair A, Neu S, Nguyen D, Norbash A, Oakley M, Obisesan TO, Ogrocki P, Ott BR, Parfitt F, Pawluczyk S, Pearlson G, Petersen R, Petrella JR, Potkin S, Potter WZ, Preda A, Quinn J, Rainka M, Reeder S, Reiman EM, Rentz DM, Reynolds B, Richard J, Roberts P, Rogers J, Rosen A, Rosen HJ, Rusinek H, Sabbagh M, Sadowsky C, Salloway S, Santulli RB, Saykin AJ, Scharre DW, Schneider L, Schneider S, Schuff N, Shah RC, Shaw L, Shen L, Silverman DH, Simpson DM, Sink

14

KM, Smith CD, Snyder PJ, Spann BM, Sperling RA, Spicer K, Stefanovic B, Stern Y, Stopa E, Tang C, Tariot P, Taylor-Reinwald L, Thai G, Thomas RG, Thompson P, Tinklenberg J, Toga AW, Tremont G, Trojanowki JQ, Trost D, Turner RS, van Dyck CH, Vanderswag H, Varon D, Villanueva-Meyer J, Villena T, Walter S, Wang P, Watkins F, Weiner M, Williamson JD, Wolk D, Wu CK, Zerrate M, Zimmerman EA. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010 May 17.

86. Escabi Y, San Miguel L, Judd T, Hertza J, Nicholson J, Schiff W, Bell C, Estes B, Millikin C, Shelton P, Marotta P, Wingler I, Barth J, Parmenter B, Andrews G, Riordan P, Lipinski D, Sawyer J, Brewer V, Kirk J, Green C, Kirkwood M, Brooks B, Fay T, Barlow K, Chelune G, Duff K, Wang A, Franchow E, Card S, Zamrini E, Foster N, Duff K, Chelune G, Wang A, Card S, Franchow E, Zamrini E, Foster N, Green D, Polikar R, Clark C, Kounios J, Malek-Ahmadi M, Kataria R, Belden C, Connor D, Pearson C, Jacobson S, Yaari R, Singh U, Sabbagh M, et al Grand rounds Arch Clin Neuropsychol. 2010 Sep;25(6):475-583

87. Charles H. Adler, M.D., Ph.D.; John N. Caviness, M.D.; Marwan N. Sabbagh, M.D.; Holly A. Shill, M.D.; Donald J. Connor, Ph.D., Ph.D.; Lucia Sue, B.S.; Virgilio G.H. Evidente, M.D.; Erika Driver-Dunckley, M.D.; Thomas G. Beach, M.D., Ph.D. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment, Acta Neuropathologica 2010 Sept 14 [epub ahead of print]

88. Geula C, Sabbagh M, Efthymiopoulos S., Friedland, RP. The 4 th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East. Amyloid 17:86-90, 2010.

89.Sabbagh MN, Malek Ahmadi M, Kataria R, Belden C, Connor DJ, Pearson C, Yaari R, Singh U. The Alzheimer’s Questionnaire: A Pilot Study for a New Informant-Based Dementia Assessment. Journal of Alzheimer’s Disease 2010; Oct 7. [Epub ahead of print]

90.Cole L, Belden C, Jacobson S, Myers K, Reininger C, Berk C, Sabbagh M. Probable early onset Alzheimer’s disease in an Apolipoprotein E2 homozygote. Dementia and Geriatric Cognitive Disorders 2010 Oct 23;30(5):387-391. [Epub ahead of print]

91.Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton LR, Leuers DC, Masliah E, Nicoll JAR, Sabbagh MN, Beach TG, Castano EM, Roher AE, The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7;5:39.

92.Sabbagh MN, Agro A, Bell J, Aisen P, Schweiser E, Galasko D. Safety and Tolerability of PF-04494700, an oral inhibitor of RAGE, in Alzheimer’s disease subjects. Alzheimer’s Disease and Associated Disorders 2010 Dec 28. [Epub ahead of print]

93. Clark CM1,2, Schneider JA3, Bedell BJ4,5, Beach TG6, Mintun MA1,7, Pontecorvo MJ1, Hefti F1, Carpenter A1, Flitter M1, Krautkramer M1, Kung HF2, Coleman RE8, Fleischer A9,10, Sabbagh M, Sadowsky C, Doraiswamy PM8, Reiman EM9, Skovronsky DM1, and the AV45-A07 study group. Validation of Florbetapir-PET for Imaging Alzheimer’s Disease Amyloid Pathology. JAMA 2011; 305(3):275-283.

94.Roher AE, Marouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG. Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient. Journal of Alzheimer’s Disease 2011 Jan 24. [Epub ahead of print]

95.Beach TG, Maarouf CL, Brooks RG, Shirohi S, Daugs ID, Sue LI, Sabbagh MN, Vedders L, Walker DG, Lue LF, Roher AE. Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimer’s disease. BMC Geriatrics 2011 Jan 25;11(1):3. [Epub ahead of print]

96. Damian AM, Jacobson SA, Hentz JG, Belden C, Shill HA, Sabbagh MN, Caviness JN, Adler CH. Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment. Dement Geriatr Cogn Disord . 2011 Jan 29;31(2):126-131. [Epub ahead of print]

15

97.Caselli RJ, Dueck AC, Locke DEC, Sabbagh MN, Ahern GL, Rapscak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM. Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers. Neurology 2011 Feb 16. [Epub ahead of print]

98.Roher AE, Garami Z, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Belohlavek M, Vedders L, Connor D, Sabbagh MN, Beach TG. Emmerling MR, Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer’s disease Alzheimer’s and Dementia 2011 Mar 8. [Epub ahead of print]

99.Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Emmerling MR, Garami Z, Belohlavek M, Sabbagh MN, Sue LI, Beach TG. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia Alzheimer’s and Dementia 2011 Mar 8. [Epub ahead of print]

100. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP? Parkinsonism Relat Disord. 2011 Mar 18. [Epub ahead of print]

101. 1CH Adler, MD, PhD, 2JG Hentz, MS, 3HA Shill, MD, 3MN Sabbagh, MD, 1E Driver-Dunckley, MD, 1VGH Evidente, MD, 3SA Jacobson, MD, 3TG Beach, MD, PhD, 4B Boeve, 1JN Caviness, MD Increased prevalence of RBD in Parkinson’s disease but not in Essential Tremor or RLS Parkinson’s Disease and Related Disorders 2011 Apr 7. [Epub ahead of print]

102. Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, Beach TG. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol. 2011 May 1. [Epub ahead of print]

103. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, Sadeghi R, Driver-Dunckley E, Evidente VG, Sabbagh MN, Shill HA, Walker DG. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord. 2011 May 3. doi: 10.1002/mds.23697. [Epub ahead of print]

104. Caviness JN, Adler CH, Hentz JG, Shill HA, Evidente VG, Driver-Dunckley ED, Sabbagh MN, Sue L, Beach TG. Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol. 2011 May 25. [Epub ahead of print]

105. Klassen BK, Hentz JG, Shill HA, Driver-Dunckley ED, Evidente VGH, Sabbagh MN, Adler CH, Caviness JN. Quantitative EEG as a Predictive Biomarker for Parkinson's disease dementia. Neurology 2011 Jun 1. [Epub ahead of print]

106. Virgilio Gerald H. Evidente, Charles H. Adler, Marwan N. Sabbagh, Donald J. Connor, Joseph G. Hentz, John N. Caviness, Lucia I. Sue, Thomas G. Beach. Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP? Parkinsonism & Related Disorders 2011; Volume 17, Issue 5, Pages 365-371

107. Cabral D, Beach TG, Vedders LJ, Sue LI, Jacobson SA, Myers K, Sabbagh MN. Frequency of Alzheimer’s Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus. Alzheimer’s and Dementia 2011 Jun 30. [Epub ahead of print]

108. Breitner, J.C., Baker, L.D., Montine, T.J., Lyketsos, C.G., Ashe, K.H., Brandt J., Craft, S., Evans, D.E., Green, R.C., Ismail, M.S., Martin, B.K., Meinert, C.L., Mullan M.M., ,Sabbagh, M., Tariot, P. for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimer’s disease pathogenesis. Alzheimer’s and Dementia 2011 Jul;7(4):402-11.

109. Gonzales A, DeCourt B, Walker A, Condjella R, Nural H, Sabbagh MN. Development of a specific ELISA to measure BACE1 levels in human tissues. Journal of Neuroscience Methods 2011; 202: 70– 76

16

110. Shill HA1, Adler CH2, Beach TG1, Lue LF1 Caviness JN, Sabbagh MN1, Sue LI1, Campbell A, Sadeghi R1 Walker DG. Brain biochemistry in autopsied patients with essential tremor. Movement Disorders 2011 Oct 28. doi: 10.1002/mds.24004. [Epub ahead of print]

111.Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, Pontecorvo M, Mintun M, Skovronsky D, Jacobson SA, Sue LI, Liebsack C, Charney AS, Cole L, Belden C, Beach TG. Positron Emission Tomography and neuropathological estimates of fibrillar amyloid-β in a Down syndrome patient with Alzheimer’s disease. Archives of Neurology 2011; 68:1461-1466.

112. Chera L. Maarouf1, Ian D. Daugs1, Tyler A. Kokjohn1,2, Douglas G. Walker3, Jesse M. Hunter1, Jane C. Kruchowsky3, Randy Woltjer4, Jeffrey Kaye5, Eduardo M. Castaño6, Marwan N. Sabbagh7, Thomas G. Beach8 and Alex E. Roher1* Alzheimer’s disease and non-demented high pathology control nonagenarians: Comparing and contrasting the biochemistry of cognitively successful aging. PLoS One. 2011;6(11):e27291. Epub 2011 Nov 7.

113. Thomas G. Beach, Lucia I. Sue, Douglas G. Walker, Marwan N. Sabbagh, Geidy Serrano, Brittany Dugger, Monica Mariner, Kim Yantos, Jonette Henry-Watson, Glenn Chiarolanza, Jose Hidalgo and Leslie Souders. Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimer’s Disease: Implications For Amyloid Imaging. Journal of Alzheimer’s Disease 2011 Nov 23. [Epub ahead of print] 28: 1-8.

114. Brittany N. Dugger, Geidy E. Serrano, Lucia I. Sue, Douglas G. Walker, Charles H. Adler*, Holly A. Shill, Marwan N. Sabbagh, John N. Caviness*, Jose Hidalgo, Megan Saxon-LaBelle, Glenn Chiarolanza, Monica Mariner, Jonette Henry-Watson, Thomas G. Beach, and the Arizona Parkinson’s Disease Consortium Presence of Striatal Amyloid Plaques in Parkinson’s Disease Dementia Predicts Concomitant Alzheimer’s Disease. Journal of Parkinson’s disease, 2012 Jan 1;2(1):57-65.

115. Shill HA, Adler CH, Beach TG, Lue L, Caviness JN, Sabbagh MN, Sue LI, Walker DG. Brain biochemistry in autopsied patients with essential tremor. Mov Disord 2012;27:113-117.

116. Reisa Sperling; Stephen Salloway; David J Brooks; Donatella Tampieri; Jerome Barakos; Nick C Fox; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Ivan Lieberburg; H. Michael Arrighi; Kristen A Morris; Yuan Lu; Enchi Liu; Keith M Gregg; Robert H Brashear; Gene G Kinney; Ronald Black; Michael Grundman, Amyloid related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with bapineuzumab: risk factors and clinical characteristics. Lancet Neurology 2012 DOI:10.1016/S1474-4422(12)70015-7

117. Malek-Ahmadi M, Davis K, Belden C, Jacobson S, Sabbagh MN. Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment). BMC Geriatrics 2012, 12:3 (3 February 2012)

118. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012 Feb 27. doi: 10.1111/j.1750-3639.2012.00585.x. [Epub ahead of print]

119. Malek-Ahmadi M, Davis K, Belden C, Laizure B, Jacobson S, Yaari R, Singh U, Sabbagh MN. Validation and diagnostic accuracy of the Alzheimer's questionnaire. Age Ageing. 2012 May;41(3): 396-9. Epub 2012 Feb 23.

120. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind

17

B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3985-90. Epub 2012 Feb 16. PMID: 22343285 [PubMed - indexed for MEDLINE]

121. Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, Sabbagh MN, Beach TG, Roher AE. Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimer’s disease. PLoS One. 2012;7(5):e36893

122. *Haijun Tian, PhD, *Safiya Abouzaid, PharmD, *Marwan N. Sabbagh MD, FAAN, Wei Chen, *Susan Gabriel, MSc, *Kristijan H. Kahler PhD, RPh, *Edward Kim, MD, MBA, Health Care Utilization and Costs among Patients with AD with and without Dysphagia, Alzheimer’s disease and Associated Disorders 2012 May 16. [Epub ahead of print] PMID: 22596081

123. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, Mintun MA, Pontecorvo MJ, Coleman RE, Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2012 May 24. [Epub ahead of print]

124.Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doriswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkrammer MJ, Lu M, Mintun MA, Skovronsky DM for the A16 study group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β-plaques: a prospective cohort study. The Lancet Neurology 2012. Jun 27. [Epub ahead of print]

125. Murali Doraiswamy; Reisa A Sperling, M.D.; Edward Coleman, MD; Keith Johnson, MD; Eric M Reiman, MD; Mat D Davis, MS; Michael Grundman, MD; Marwan N Sabbagh, MD; Carl H Sadowsky, MD; Adam Fleisher, MD; Alan Carpenter, PhD; Christopher M Clark, MD; Abhinay D Joshi,MS; Mark A Mintun, MD; Daniel M Skovronsky, MD; Michael J Pontecorvo, PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline: A multi-center longitudinal study Neurology WNL.0b013e3182661f74; published ahead of print July 11, 2012,

18

126. Decourt, B; Walker, A; Gonzales, A; Malek-Ahmadi, M; Liebsack, C; Davis, K; Belden, C; Jacobson, S; Sabbagh, M. Can platelet BACE1 levels be used as a biomarker for Alzheimer’s disease? Proof-of-concept study. Platelet 2012 (Jul 9. [Epub ahead of print]

127. Damian A, Adler CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Evidente VG, Beach TG, Driver-Dunckley E. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord . 2012 Jul 6. [Epub ahead of print]

128. Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, Hock C, Kunz M, Kuhlmann J, Reininger C, Blankenburg M. Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimer's Disease. Dement Geriatr Cogn Disord. 2012 Jul 20;33(6):416-422. [Epub ahead of print]

129. Reisa Sperling; Keith A. Johnson; P. Murali Doraiswamy; Eric M. Reiman; Adam S. Fleisher; Marwan Sabbagh, Carl Sadowsky, Alan Carpenter, Christopher M. Clark, Mat Davis, Matthew Flitter, Abhinay Joshi, Mark Mintun, Daniel Skovronsky, Michael Pontecorvo for the AV45-A05 Study Group. Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7. [Epub ahead of print]

130. Maarouf CL, Beach TG, Adler CH, Shill HA, Sabbagh MN, Wu T, Walker DG, Kokjohn TA, Roher AE; Arizona PD Consortium. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res . 2012 Sep;34(7):669-76.

131. Brittany N. Dugger, Geidy E. Serrano, Lucia I. Sue, Douglas G. Walker, Charles H. Adler*, Holly A. Shill, Marwan N. Sabbagh, John N. Caviness*, Jose Hidalgo, Megan Saxon-LaBelle, Glenn Chiarolanza, Monica Mariner, Jonette Henry-Watson, Thomas G. Beach, and the Arizona Parkinson’s Disease Consortium Presence of Striatal Amyloid Plaques in Parkinson’s Disease Dementia Predicts Concomitant Alzheimer’s Disease. Journal of Parkinson’s disease, 2012 Jan 1;2(1):57-65.

132. Sabbagh MN, Ahmadi MM, Levenson I, Sparks DL. KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease Patients. Journal of Alzheimer’s Disease2012 Aug 22. [Epub ahead of print]

133. Goldknopf I, Park H, Sabbagh MN. Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimer’s Disease Patients vs. Parkinson’s Disease Patients and Age-matched Normal Controls contribution Current Alzheimer’s Research 2012 Aug 29. [Epub ahead of print]: 1149-1167.

134. Kaur B, Harvey DJ, DeCarli C, Zhang L, Sabbagh MN, Olichney JM. Extrapyramidal signs by dementia severity in Alzheimer’s disease and dementia with Lewy bodies Alzheimer’s Disease and Associated Disorders 2012 Sep 27. [Epub ahead of print]

135. Decourt B, Gonzales A, Beach TG, Malek-Ahmadi M, Walker A, Sue L, Walker DG, Sabbagh MN. BACE1 levels by ApoE genotype in non-demented and Alzheimer’s postmortem brains Current Alzheimer’s Research 2012 October 2 [epub ahead of print]

136. Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, Hunter JM, Kokjohn TA, Walker DG, Kruchowsky JC, Belohlavek M, Sabbagh MN, Beach TG. Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag. 2012;8:599-611. Epub 2012 Oct 23.

137. Michael Malek-Ahmadi, Kathryn Davis, Christine M. Belden, Marwan N. Sabbagh Comparative Analysis of the Alzheimer’s Questionnaire (AQ) with the CDR Sum of Boxes, MoCA, and MMSE Alzheimer’s Disease and Associated Disorders 2012 Nov 7. [Epub ahead of print]

138. Walker DG, Lue LF, Adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG; Arizona Parkinson Disease Consortium. Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains. Exp Neurol . 2012 Nov 28. doi:pii: S0014-4886(12)00437-2. 10.1016/j.expneurol.2012.11.020. [Epub ahead of print] 240 (2013) 190–204

19

139. Castaño EM, Maarouf CL, Wu T, Leal MC, Whiteside CM, Lue LF, Kokjohn TA, Sabbagh MN, Beach TG, Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations. Neurochem Int. 2012 Dec 8. doi:pii: S0197-0186(12)00391-9. 10.1016/j.neuint.2012.12.001. [Epub ahead of print]

140. Kokjohn TA, Maarouf CL, Daugs ID, Hunter JM, Whiteside CM, Malek-Ahmadi M, Rodriguez E, Kalback W, Jacobson SA, Sabbagh MN, Beach TG, Roher AE. Neurochemical profile of dementia pugilistica. J Neurotrauma . 2012 Dec 26. [Epub ahead of print]

141. Delvaux E, Bentley K, Stubbs V, Sabbagh M, Coleman PD. Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes. Neurobiol Aging . 2013 Jan 5. doi:pii: S0197-4580(12)00619-7.[Epub ahead of print]

142. Sparks DL, Kryscio RJ, Ziolkowski C, Lin Y, Sabbagh MN, Sparks LM, Liebsack C, Johnson-Traver S. Tau levels are reduced in AD plasma and validation of ELISA methods employed. Am J Neurodegener Dis 2012;1(1):99-106.

143. Beach TG, Adler CH, Dugger BN, Serrano G, Hidalgo J, Henry-Watson J, Shill HA, Sue LI, Sabbagh MN, Akiyama H; the Arizona Parkinson’s Disease Consortium. Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. J Neuropathol Exp Neurol. 2013 Feb;72(2):130-136.

144. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, Reiman EM, Sabbagh MN, Sadowsky CH, Fleisher AS, Murali Doraiswamy P, Carpenter AP, Clark CM, Joshi AD, Lu M, Grundman M, Mintun MA, Pontecorvo MJ, Skovronsky DM; AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013 Jan 30. S1552-5260(12)02517-4. [Epub ahead of print]

145. Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimers Res Ther. 2013 Feb 21;5(1):12. [Epub ahead of print]

146. Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, Santamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duyckaerts C, Schenck CH, Mahowald MW, Dauvilliers Y, Graff-Radford NR, Wszolek ZK, Parisi JE, Dugger B, Murray ME, Dickson DW. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013 Mar 6. pii: S1389-9457(12)00387-5. doi: 10.1016/j.sleep.2012.10.015. [Epub ahead of print]

147. Michael Malek-Ahmadi MSPH1, Vickram Kahlon1, Charles H Adler MD, PhD2, Aleksandra Obradov1, Kabir Thind MD1, Holly A Shill MD1,4, Lucia I Sue BS3, John N. Caviness MD2, Sandra Jacobson MD1,4, Marwan N Sabbagh MD1,4*Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort. Clinical and Experimental Medical Sciences 2013; 1 (7) 317-327.

148. Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, Walker DG, Shill HA, Jacobson SA, Sabbagh MN, Roher AE; Arizona Parkinson’s Disease Consortium. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights . 2013;8:19-28. doi: 10.4137/BMI.S11422. Epub 2013 Mar 12.

149. Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG. Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS One. 2013;8(3):e59735. doi: 10.1371/journal.pone.0059735. Epub 2013 Mar 21.

20

150. Michael Malek-Ahmadi1 MSPH, Thomas Beach1 MD, PhD Aleksandra Obradov1 BS, Lucia Sue1 BS, Christine Belden1 PsyD, Kathryn Davis1 BA, Douglas G. Walker1 PhD, LihFen Lue1 PhD, Abdu Adem2 PhD, Marwan N. Sabbagh1 MD Type 2 diabetes is associated with increased Alzheimer’s disease neuropathology in ApoE ε4 Carriers Current Alzheimer’s Research 2013 Apr 29. [Epub ahead of print]

151. Myers K, Capek D, Shill H, Sabbagh M. Aquatic Therapy and Alzheimer’s disease. Annals of Long Term Care: Clinical Care and Aging. 2013; 21(5): 36-41.

152. Sabbagh MN, Malek-Ahmadi M, Dugger B, Lee K, Sue L, Serrano G, Walker DG, Davis KJ, Jacobson SA, Beach TG. The influence of the apolipoprotein E genotype on regional pathology in Alzheimer’s Disease. BMC Neurology 2013 13:44.DOI: 10.1186/1471-2377-13-44

153. Marwan Sabbagh, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Liang Liu, Joan Mackell and et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatrics 2013 Jun 6;13(1):56.

154. Roher AE, Maarouf CL, Malek-Ahmadi M, Wilson J, Kokjohn TA, Daugs ID, Whiteside CM, Kalback WM, Macias MP, Jacobson SA, Sabbagh MN, Ghetti B, Beach TG. Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations. Am J Neurodegener Dis. 2013 Sep 18;2(3):187-207.

155. Shneyder N, Adler CH, Hentz JG, Shill H, Caviness JN, Sabbagh MN, Beach TG, Driver-Dunckley E. Autonomic complaints in patients with restless legs syndrome. Sleep Med. 2013 Sep 21. doi:pii: S1389-9457(13)01100-3. 10.1016/j.sleep.2013.08.781. [Epub ahead of print]

156. Johnson KA, Sperling RA, Gidiscin CM, Carmasin JS, Maye JE, Coleman RE, Reiman EM, Sabbagh MN;,Sadowsky CH, Fleisher AS, Doriswamy MP, Carpenter AP, Clark CM, Joshi AD, Lu M, Grundman M, Mintun MA, Pontecorvo MJ, Skovronsky DM for the AV 45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimer’s and Dementia 2013; 9(5supplement) S72-83.

157. Henderson-Smith A, Chow D, Meechoovet B, Aziz M, Jacobson SA, Shill HA, Sabbagh MN, Caviness JN, Adler CH, Driver-Dunckley ED, Beach TG, Yin H, Dunckley T. SMG1 Identified as a Regulator of Parkinson's Disease-Associated alpha-Synuclein through siRNA Screening. PLoS One. 2013 Oct 30;8(10):e77711. doi: 10.1371/journal.pone.0077711.

158. MiMi P Macias, Amanda M Gonzales, Ashley L Siniard, Aaron W Walker, Jason J Corneveaux, Matthew J Huentelman, Boris Decourt, Marwan N Sabbagh. A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production. J Neurosci Methods. 2013 Dec 12. pii: S0165-0270(13)00413-5.

159. Malek-Ahmadi M, Patel A, Sabbagh MN. KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease Patients, International Journal of Alzheimer’s Disease 2013. doi:10.1155/2013/242303.

160. Maarouf CL, Kokjohn TA, Whiteside CM, Macias MP, Kalback WM, Sabbagh MN, Beach TG, Vassar R, Roher AE. Molecular differences and similarities between Alzheimer’s disease and the 5x FAD Transgenic Mouse Models of Amyloidosis. Biochemistry Insights 2013;6:1-10

161. Aaron H Burstein , Imogene Grimes , Douglas R Galasko , Paul S Aisen , Marwan Sabbagh, Adnan MM Mjalli. Effect of TTP488 in patients with mild to moderate Alzheimer's disease BMC Neurology 2014, 14:12 (15 January 2014)

162.Stephen Salloway*, M.D., M.S.,1 Reisa Sperling*, M.D., M.MSc.2 Nick C. Fox, M.D., F.R.C.P,3 Kaj Blennow, M.D.,4 William Klunk, M.D.,5 Murray Raskind, M.D.,6 Marwan Sabbagh, M.D.,7 Lawrence S. Honig, M.D., Ph.D.,8 Anton Porsteinsson, M.D.,9 Steven Ferris Ph.D.,10 Marcel Reichert, M.D.,11 Nzeera Ketter, M.D.,11 Bijan Nejadnik, M.D.,11 Volkmar Guenzler, M.D.,11 Maja Miloslavsky, Ph.D.,11 Daniel Wang, Ph.D.,11 Cristina Tudor, Ph.D, 11 Julia Lull, MA,12 Yuan Lu, MS,11 Enchi Liu, Ph.D.,11 Michael Grundman, M.D., M.P.H.,13,14 Eric Yuen, M.D.,11 Ronald Black, M.D.,15 and H. Robert

21

Brashear, M.D.11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators** Intravenous bapineuzumab in mild-to-moderate Alzheimer disease: Phase 3 clinical trial results in apolipoprotein E ε4 carriers and non-carriers, New England Journal of Medicine 2014:370:322-333.

163. Brittany N. Dugger PhDb, Christopher M. Clark MDa┼, Geidy Serrano PhDb, Monica Mariner BSb, Barry J. Bedell MD PhDc, R. Edward Coleman MDd┼, P. Murali Doraiswamy MDd, Ming Lua, Adam S. Fleisher MD MASe, Eric M. Reiman MDe, Marwan N. Sabbagh MDb, Carl H. Sadowsky MDf, Julie A. Schneider MDg, Simone P. Zehntner PhDc, Alan P. Carpenter PhDa, Abhinay D. Joshi PhDa, Mark A. Mintun MDa, Michael J. Pontecorvo PhDa, Daniel M. Skovronsky MD PhDa, Lucia I. Sue BSb, Thomas G. Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem Correlates J Neuropathol Exp Neurol . 2014 Jan;73(1):72-80.

164.Brittany N. Dugger PhD1, Joseph G. Hentz MS2, Charles H. Adler MD, PhD2, Marwan N. Sabbagh MD1, Holly A. Shill MD1, Sandra Jacobson MD1, John N. Caviness MD2, Christine Belden PhD1, Erika Driver-Dunckley MD2, Kathryn J. Davis BS1, Lucia I. Sue BS1 and Thomas G. Beach MD,PhD1 and the Arizona Parkinson’s Disease Consortium. Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. J Neuropathol Exp Neurol. 2014 Jan 30. [Epub ahead of print]

165. P. Murali Doraiswamy, Reisa Sperling, Keith Johnson, Eric Reiman, Terence Wong, Marwan Sabbagh, Carl Sadowsky, Adam Fleisher, Alan Carpenter, Abhinnay Joshi, Ming Lu, Michael Grundman, Mark Mintun, Daniel Skovronsky, and Michael Pontecorvo, Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study, Molecular Psychiatry 11 March 2014; doi:10.1038/mp.2014.9

166.Douglas Galasko 1, Joanne Bell 2, Jessica Mancuso 2James Kupiec2, Marwan Sabbagh3, Christopher van Dyck4, Ronald G. Thomas 1, Paul S. Aisen1, for the ADCS A clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer’s disease. Neurology 2014 Apr 29;82(17):1536-42. doi: 10.1212/. Epub 2014 Apr 2.

167. Andrew Siderowf1, Michael J. Pontecorvo1, Holly A. Shill2, Mark A. Mintun1, Anupa Arora1, Abhinay D. Joshi1, Ming Lu1, Charles H. Adler3, Douglas Galasko4, Carolyn Liebsack2, Daniel M. Skovronsky1, Marwan N. Sabbagh2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging of Dopamine Degeneration With 18F-AV-133 (Florbenazine) in Patients with Alzheimer’s Disease and Lewy Body Disorders. BMC Neurology 2014 BMC Neurol. 2014 Apr 9;14:79. doi: 10.1186/1471-2377-14-79.

168. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N; Arizona Parkinson's Disease Consortium. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett. 2014 Jun 13;571:34-8. doi: 10.1016/j.neulet.2014.04.027. Epub 2014 Apr 28.

169. Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. Neurobiol Aging. 2014 Sep;35(9):1961-72. doi: 10.1016/j.neurobiolaging.2014.03.031. Epub 2014 Apr 2.

170. Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, Shill H, Adler C, Sabbagh M, Villa S, Tembe W, Craig D, Van Keuren-Jensen K. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One. 2014 May 5;9(5):e94839. doi: 10.1371/journal.pone.0094839. eCollection 2014

171. Serrano GE, Sabbagh MN, Sue LI, Hidalgo JA, Schneider JA, Bedell BJ, Van Deerlin VM, Suh E, Akiyama H, Joshi AD, Pontecorvo MJ, Mintun MA, Beach TG. Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions. J Alzheimers Dis . 2014 Jun 13. [Epub ahead of print]

172. Charles H. Adler, Thomas G. Beach, Joseph G. Hentz, Holly A. Shill, John N. Caviness, Erika Driver-Dunckley, Marwan N. Sabbagh, Lucia I. Sue, Sandra A.Jacobson, Christine M. Belden, and Brittany N. Dugger, Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease:

22

Clinicopathologic Study. Neurology . 2014 Jul 29;83(5):406-12. doi: 10.1212/WNL.0000000000000641. Epub 2014 Jun 27.

173. Belden C, Kahlon VS,Ahmadi MM, Tsai A, Sabbagh MN. Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies. American Journal of Alzheimer’s Disease and Other Dementias 2014 Jul 9. pii: 1533317514542642. [Epub ahead of print]

174. Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, Shill HA, Sabbagh MN, Belden CM, Sue LI, Caviness JN, Hu C; the Arizona Parkinson's Disease Consortium. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord . 2014 Jun 28. pii: S1353-8020(14)00238-7. doi: 10.1016/j.parkreldis.2014.06.018. [Epub ahead of print]

175. Tsai A, Ahmadi MM, Kahlon V, Sabbagh MN. Differences in cerebrospinal fluid biomarkers between clinically diagnosed normal pressure hydrocephalus and Alzheimer’s disease. . Journal of Alzheimer’s Dementia and Parkinsonism 2014 . 4: 150. doi: 10.4172/2161-0460.1000150

176. Holly A. Shill, Joseph G. Hentz, Sandra Jacobson, Christine Belden, Marwan Sabbagh, Thomas G. Beach, Erika Driver-Dunckley and Charles H. Adler. Essential tremor in the elderly and risk for dementia. Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014), Article ID 328765,

177. ADAPT-FS Research group (Sabbagh MN). Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS). Alzheimer’s and Dementia 2014 Jul 8. pii: S1552-5260(14)00115-0. doi: 10.1016/j.jalz.2014.03.009. [Epub ahead of print]

178. Erika Driver-Dunckley, Charles H. Adler, Joseph G. Hentz, Brittany N. Dugger, Holly A. Shill, John N. Caviness, Marwan N. Sabbagh, Thomas G. Beach, the Arizona Parkinson Disease Consortium. Olfactory dysfunction In Incidental Lewy body disease and Parkinson’s disease . Parkinsonism and related disorders 2014 Aug 16. pii: S1353-8020(14)00304-6. doi: 10.1016/j.parkreldis.2014.08.006. [Epub ahead of print]

179. Chera L. Maarouf; Tyler A. Kokjohn; Douglas G. Walker; Charisse M. Whiteside; Walter M. Kalback; Alexis Whetzel; Lucia I. Sue; Geidy Serrano; Sandra A. Jacobson; Marwan N. Sabbagh; Eric M. Reiman; Thomas G. Beach; Alex E Roher, M.D., Ph.D, Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimer's Disease. PLOS ONE 2014 Aug 28;9(8):e105784. doi: 10.1371/journal.pone.0105784. eCollection 2014.

180. John N. Caviness1, Joseph G. Hentz1, Christine M. Belden2, Holly A. Shill2, Erika D. Driver-Dunckley1, Marwan N. Sabbagh2, Jessica J. Powell2, Charles H. Adler1. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson’s disease. J Parkinsons Dis. 2014 Nov 24. [Epub ahead of print]

181. Michael Malek-Ahmadi, MSPH; Kewei Chen, PhD; Kathryn Davis, BA; Christine .Belden, PsyD; Jessica Powell, PsyD; Sandra A. Jacobson, MD; Marwan N. Sabbagh,MD. Sensitivity to Change and Prediction of Global Change for the Alzheimer’s Questionnaire (AQ). Alzheimer's Research & Therapy.2015, 7:1; DOI: 10.1186/s13195-014-0092-z

182. Danna Jennings, John Seibyl, Marwan Sabbagh, Florence Lai, William Hopkins, Santi Bullich, Corneila Reininger, Barbara Putz, Andrew Stephens, Ana Catafau, and Ken Marek. Age dependence of brain β-amyloid deposition in Down syndrome: a [18F]florbetaben PET study. Neurology. 2015 Jan 7. pii: 10.1212/WNL.0000000000001212. [Epub ahead of print]

183. Craig Curtis , Jose Gamez , Upinder Singh , Carl Sadowsky , Teresa Villena , Marwan Sabbagh , Thomas Beach , Ranjan Duara , Adam Fleisher , Kirk Frey , Zuzana Walker , Arvinder Hunjan , Clive Holmes , Yavir Escovar , Carla Vera , Marc Agronin , Joel Ross , Andrea Bozoki , Mary Akinola , Jiong Shi , Rik Vandenberghe , Milos Ikonomovic , Paul Sherwin , Igor Grachev , Gillian Farrar , Adrian Smith , Christopher Buckley , Richard McLain , Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26, 2015. doi:10.1001/jamaneurol.2014.4144

23

184. Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, Lue L, Roher AE, Dugger BN, Maarouf C, Birdsill AC, Intorcia A, Saxon-Labelle M, Pullen J, Scroggins A, Filon J, Scott S, Hoffman B, Garcia A, Caviness JN, Hentz JG, Driver-Dunckley E, Jacobson SA, Davis KJ, Belden CM, Long KE, Malek-Ahmadi M, Powell JJ, Gale LD, Nicholson LR, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Burke AD, Reiman EM, Sabbagh MN. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology. 2015 Jan 26. doi: 10.1111/neup.12189. [Epub ahead of print]

185. Roher AE, Maarouf CL, Kokjohn TA, Whiteside CM, Kalback WM, Serrano G, Belden C, Liebsack C, Jacobson SA, Sabbagh MN, Beach TG. Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the γ-secretase inhibitor semagacestat. Am J Neurodegener Dis. 2014 Dec 5;3(3):115-33. eCollection 2014.

186. Budolfson K, Ahmadi MM, Belden CM, Powell J, Davis K, Jacobson SA, Sabbagh MN. Neuropsychological Correlates of the Alzheimer’s Questionnaire. J Alzheimers Dis. 2015 Mar 3. [Epub ahead of print]

187. Heather B. Rigby1, Brittany N. Dugger2, Joseph G. Hentz3, Charles H. Adler1, Thomas G. Beach2, Holly A. Shill4,5, Erika Driver-Dunckley1, Marwan N. Sabbagh4,5, Lucia I. Sue2, John N. Caviness1 Clinical features of patients with concomitant Parkinson’s disease and progressive supranuclear palsy pathology. Movement Disorders Clinical Practice 2014 (accepted)

188.Marwan N. Sabbagh, MD1,2,, Kewei Chen, PhD2,3,4,, Joseph Rogers, PhD5, Adam S. Fleisher, MD2,3,6,, Carolyn Liebsack, RN1,2,, Dan Bandy, MS2,3,, Christine Belden, PsyD1,2,, Pradeep Thiyyagura，MS 2,3,, Xiaofen Liu, MS 2,3,, Auttawut Roontiva, MS 2,3,, Sandra Jacobson, MD1,2,, Michael Malek-Ahmadi, MSPH1,2, , Stephanie Parks, BS2,3,, Jessica Powell PsyD1,2,, Eric M. Reiman, MD2,3,7, Florbetapir PET, FDG PET, and MRI in Down Syndrome Individuals with and without Alzheimer’s Dementia. Alzheimer’s and Dementia 2015 (in press)

189. Osama Sabri MD, Marwan N. Sabbagh MD, John Seibyl MD, Henryk Barthel MD,Hiroyasu Akatsu MD, Yasuomi Ouchi MD, Kohei Senda MD, Shigeo Murayama MD, Kenji Ishii MD, Masaki Takao MD, Thomas G. Beach MD, Christopher C. Rowe MD, James B. Leverenz MD, Bernardino Ghetti MD, James W. Ironside MD, Anja Hoffmann MD, Katrin Roth PhD, Cornelia Reininger MD, Walter J. Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group#)A phase 3 trial of whole brain and regional ß-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimer’s and Dementia 2015 (accepted)

190. Boris Decourt, Ph.D.; Aaron Walker, B.S.; Amanda Gonzales, B.S.; Michael Malek- Ahmadi, M.S.; Marwan N Sabbagh, M.D. A potential BACE1 inhibitor. Current Alzheimer’s Research 2014 (submitted)

191. Marwan Sabbagh MD1; Sandra Jacobson MD1; Christine Belden PsyD1, Zoran Obradov MD, CCRC1, Michael Malek-Ahmadi MSPH, Jessica Powell PsyD1, Atul Syal MD,2 Maninder Kahlon MD2, Jatin Shah MD2, Carolyn Liebsack RN, CCRC; Denise Drumm-Gurnee PhD.1 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 9.5mg daily. Journal of Alzheimer’s Dementia and Parkinsonism 2014 (submitted).

192.Steven D. Targum, Kristen Drake, J. Cara Pendergrass, Gwenn S. Smith, Paul B. Rosenberg, Michael S. Okun, Russell M. Bauer, Marwan Sabbagh, Paul Malloy, Andres M. Lozano, Constantine G. Lyketsos. Subject Selection for a Randomized Trial of Deep Brain Stimulation in Patients with Mild Alzheimer’s Disease. Journal of Geriatric Psychiatry and Neurology 2014 (submitted)

193. Schwenk M, Sabbagh MN, Lin I, Morgan P, Grewal G, Mohler J, Coon, DW, Najafi B. Exergaming improves balance in people with mild cognitive impairment: a randomized controlled pilot study. BMC Neurology 2015 (submitted)

Multi-Center Consortium Manuscripts

24

1. The NINDS NET-PD Investigators (Sabbagh MN) A Randomized, Double Blind, Futility Clinical Trial of Creatine and Minocycline in Early Parkinson’s Disease Neurology 2006; 66: 664-671.

2. Tilley, BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinson’s Disease: Using Futility Designs Neurology 2006; 628-633

3. Martin BK, Breitner JCS, Evans D, Lyketsos CG, Meinert CL. For the ADAPT Research Group (Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS 2006; e33:0001-0010.

4. The NINDS NET-PD Investigators (Sabbagh MN) A Randomized, Double Blind, Futility Clinical Trial of CoEnzyme Q10 and GPI1485 in Early Parkinson’s Disease Neurology 2007; 68:20-28.

5. ADAPT Research Group* Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) Results of a Randomized, Controlled Trial of Naproxen and Celecoxib (Sabbagh MN). Arch Neurol . 2008;65(7): 896-905.

6. The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008 May-Jun;31(3):141-50.

7. Cuenco KT, Green RC, Zhang J, Lunetta K, Erlich PM, Cupples LA, Farrer LA, DeCarli C; MIRAGE Study Group (Sabbagh MN). Magnetic resonance imaging traits in siblings discordant for Alzheimer disease. J Neuroimaging. 2008 Jul;18(3):268-75.

8. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study (Sabbagh MN). High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15;300(15):1774-8

9. T Cuenco K, Lunetta KL, Baldwin CT, McKee AC, Guo J, Cupples LA, Green RC, St George-Hyslop PH, Chui H, DeCarli C, Farrer LA; MIRAGE Study Group (Sabbagh MN). Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol. 2008 Dec;65(12):1640-8.

10. ADAPT Research Group (Sabbagh MN) Alzheimer’s Disease Anti-Inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer’s and Dementia 2009; 5: 93-104.

11. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative (Sabbagh MN). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009 May;132(Pt 5):1355-65.

12. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group (Sabbagh MN). Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology. 2009 Jun 16;72(24):2115-21.

13. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group (Sabbagh MN). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009 Dec 6;302(23):2557-64.

14. Xu C, Wang Z, Fan M, Liu B, Song M, Zhen X, Jiang T; Alzheimer's Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. Neuroreport. 2010 Aug 23;21(12):802-7.

15. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging. 2010 Aug;31(8):1452-62, 1462.e1-2.

25

16. Perneczky R, Wagenpfeil S, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA, Kurz A; MIRAGE Study Group. (Sabbagh MN) Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. Neurology. 2010 Jul 13;75(2):137-42.

17. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C; Alzheimer's Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol. 2010 Nov;67(11):1370-8.

18. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug;68(8):853-61.

19. McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative(Sabbagh MN). Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology. 2011 Jun;259(3):834-43. Epub 2011 Apr 6.

20. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative (Sabbagh MN). Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology. 2011 Jun;259(3):844-51. Epub 2011 Apr 5.

21. Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative (Sabbagh MN), Goate AM. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.PLoS One. 2011 Feb 9;6(2):e1591.

22. Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RC, Griffith P, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA; Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol. 2011; Dec;68(12):1569-79.

23. Swaminathan S, Huentelman MJ, Corneveaux JJ, Myers AJ, Faber KM, Foroud T, Mayeux R, Shen L, Kim S, Turk M, Hardy J, Reiman EM, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative and NIA-LOAD/NCRAD Family Study Group. Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. PLoS One. 2012;7(12):e50640. doi: 10.1371/journal.pone.0050640. Epub 2012 Dec 5.

24. Jahanshad N, Rajagopalan P, Hua X, Hibar DP, Nir TM, Toga AW, Jack CR Jr, Saykin AJ, Green RC, Weiner MW, Medland SE, Montgomery GW, Hansell NK, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Thompson PM; the Alzheimer’s Disease Neuroimaging Initiative. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A. 2013 Mar 5. [Epub ahead of print]

Abstracts (over 200 total)

INVITED PRESENTATIONS: over 100 invited presentations

Completed Research SupportShort-Term Training: Students in Health Professional Schools, NIH #HL07479 1990-1991, PI,

(funded) $2500

The Stein Institute for Research on Aging (SIRA): Start-up grant, 1996-7 UCSD # IRASABB, PI,(funded), $7500

26

Pfizer/Eisai: Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo. Co-PI (funded) Co-Investigator, $22,500

NIA/Johns Hopkins University: Alzheimer’s Disease Anti-Inflammatory Prevention Trial –ADAPT (funded) Site Principal Investigator, Fixed Costs/Budget, Site PI, $129,855/year x 10 years

A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimer’s Disease (funded) Co- Investigator ISOA/ Pfizer, Co-I, $350,000/year x 3 years

Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project, (funded) $5,000 x 1 year SHRI#109803

In vivo effects of nicotine on AD in animal models. (Principal Investigator) Arizona Alzheimer’s Research Center $12,000 (funded)

Reaching out to the mind and spirit of the elderly Native American. (Principal investigator) Pfizer unrestricted educational grant $5000 (funded),

ADCC/Indian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20,000 (funded)

Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease. (Principal Investigator) ADCC pilot $25,000 (funded)

Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted educational grant $10,000 (funded)

Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological unrestricted educational grant $20,000 (funded)

Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational grant $20,000 (funded)

Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo. (Funded) PI, Institute of Mental Health Research $25,000 (funded)

Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA ADCC supplemental educational grant $97,000 (funded)

Creation and Validation of an Alzheimer’s Questionnaire. ADCC pilot $25,000, PI (funded)

The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-NACC-ADCC Supplement) Co-PI $87,500 (funded) (Site PI)

Study of thalidomide as a BACE1 inhibitor in Alzheimer’s disease (Co-PI) NIA R01 $1,700,000 (funded) R01AG034155

A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 9.5mg daily (PI) Eisai, (funded)

27

NIA U01 AG15477-01A2 (PIs: Breitner/Sabbagh): 1/1/10 –7/31/13. Sabbagh Role: Multi Principal InvestigatorPrevention of Alzheimer’s Dementia and Cognitive DeclineThis is a continuation grant of the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs. This project aims to follow the cohort for another five years to learn whether these cognitive effects grow, stabilize, or reverse.

Arizona Alzheimer’s Research Consortium (AARC) AZ-DHS (PI: Reiman): 7/1/13 – 6/30/14, Sabbagh Role: Principal InvestigatorComparison of Alzheimer’s disease and Down syndrome post-mortem brain markers.Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains, at each stage in the progression of clinical and neuropathological AD.

Arizona Alzheimer’s Research Consortium (AARC) AZ-DHS (PI: Reiman): 7/1/11-6/30/12. Sabbagh Role: Co-InvestigatorFibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimer’s Disease.

Arizona Biomedical Research Commission 0011(PI: Adler): 10/1/09 to 9/30/12. Sabbagh Role: Co-InvestigatorArizona Parkinson’s Disease CenterThis project is for continuing funding for the operations of an Arizona Parkinson’s Disease Center that includes a Clinical Core directed by Dr. Sabbagh.

NIH (via Subcontract) R01 (PI: Aisen/Siffert): 1/25/10-1/30/12. Sabbagh Role: Principal Investigator on subcontractA Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer’s Disease. This project is for the requisite skills, facilities, and resources to enroll patients and conduct the study.

Current Research SupportADHS14-00003606 10/23/14-10/22/17 1.44 calendar Principal InvestigatorArizona Biomedical Research Comm $223,816 Annual DCLongitudinal Assessment of Florbetapir FET, FDG PET, and MRI in Down SyndromeCharacterize and quantify various biomarkers for DS progression in its early or preclinical phase.

5P30 AG019610 (Reiman) 7/1/11-6/30/16 0.36 calendar Clinical Site PI/ NIH $101,435 (BSHRI clinic Annual DC) Co-InvestigatorArizona Alzheimer’s Disease Core Center – Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies.

U24NS072026 (Beach) 9/1/11-6/30/16 0.24 calendar Co-InvestigatorNINDS $1,012,965 Annual DC National Brain and Tissue Resource for Parkinson's Disease and Related DisordersAssist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere.

2R01AG007367 (Rogers) 8/1/12 – 7/31/15 0.12 CalendarPI on Subcontract

NIH/NIA subcontract (Sabbagh) $33,198 Annual DC

28

Alzheimer's disease: a blood diagnostic and biomarker of disease progressionDevelop an inexpensive, safe blood test based on erythrocyte A levels that can diagnose AD.β

NIRG-12-237512 (DeCourt) 10/1/12 – 9/30/14 0.12 calendar Co-InvestigatorAlzheimer’s Association $45,455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice.

AARC (Sabbagh/Reiman/Adler) 7/1/14 – 6/30/15 .36 calendarPrincipal Co-Investigator

State of Arizona DHS $35,000 Annual DC(DHS) and Sun Health Foundation (match)Long-Term Consequences of Repetitive Brain Injury in Athletes: A Longitudinal Study with Eventual Brain Donation

AARC (Sabbagh) 7/1/14 – 6/30/15 .24 calendarPrincipal Investigator

State of Arizona DHS $75,000 Annual DC(DHS) and Sun Health Foundation (match)Florbetapir PET, and MRI in Down Syndrome Individuals with and without Alzheimer’s Dementia

ADHS 14-082998 10/23/14-10/22/17 Arizona Biomedical Research Commission (ABRC) Longitudinal Assessment of Florbetapir FET, FDG PET, Tau, and MRI in Down SyndromeCharacterize and quantify various biomarkers for DS progression in its early or preclinical phase.Role: Principal Investigator AARC FYE 2015 (Sabbagh/Reiman/Adler) 7/1/14 – 6/30/15 State of Arizona DHS (DHS) and Sun Health Foundation (match)Long-Term Consequences of Repetitive Brain Injury in Athletes: A Longitudinal Study with Eventual Brain DonationRole: Principal Co-Investigator AARC FYE 2015 (Sabbagh) 7/1/14 – 6/30/15 State of Arizona DHS (DHS) and Sun Health Foundation (match)Florbetapir PET, and MRI in Down Syndrome Individuals with and without Alzheimer’s Dementia Role: Principal Investigator

MULTI-INSTITUTIONAL STUDIESAlzheimer’s disease Neuroimaging Initiative (Site PI)Multi-institutional Research in Alzheimer’s Genetic Epidemiology (Site PI)Alzheimer’s disease Cooperative Study (Site PI)DOD-ADNI (Site PI)

COMMITTEES: Steering Committee, ADAPT trial ADCC Grants Management Committee, State of Arizona/NIAAARC Internal Scientific Advisory Committee, State of ArizonaADCC Diversity Committee, State of ArizonaBehavioral Neurology Section, American Academy of NeurologyGeriatric Neurology Section, American Academy of NeurologyAlzheimer’s Study GroupGeriatric Neurology Board Examination Committee, United Council of Neurological Subspecialties

29

CLINICAL Over 100 clinical trials that Dr Sabbagh has been site PI for. Here is the list of his role as national PI

A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimer’s Disease (Co-Principal Investigator) ISOA/ Pfizer

Alzheimer’s Disease Anti-Inflammatory Prevention Trial –ADAPT (funded) Site Principal Investigator, NIA/Johns Hopkins University

A double-blind, randomized, placebo-controlled, phase Iia, multiple dose, multicenter study in patients with mild to moderate dementia of the Alzheimer’s type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488. TransTech Pharma (National PI).

Blood Serum Biomarkers for Neurodegenerative Diseases: Differential Diagnosis of Neurodegenerative Diseases, Alzheimer’s, Parkinson’s, and Like Disorders Protocol Number: NAA-0001-S 11/8/2007 Power 3 Medical Products (National PI)

Diagnosis of Alzheimer’s Disease Using PBL Mitogenic Stimulation Phase 3. ProVista Life Sciences (National Co-PI)

An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimer’s Disease DIM13. Medivation (National Co-PI)

Bayer Piramal - An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compared to postmortem histopathology (National Co-PI)

TTP488 - randomized, double-blind, placebo controlled, multi-center registration trial to evaluate the efficacy and safety of ttp488 in patients with mild alzheimer's disease receiving acetylcholinesterase inhibitors and/or memantine (National Co-PI)

A complete accounting of all clinical trials is available separately.

30